ERBB2 and neoplasm: Of note, the ERBB2 (HER2) amplification was validated in SEC1 at the protein level, in which HER2 membranous expression by IHC (2+) was seen in the primary tumor region, being even more intense in both the metastatic sections analyzed (Fig. 4G), suggesting anti-HER2 therapy as a potential treatment option in this patient.